BioCryst Announces Partnerships for Peramivir for Influenza Outsid...( BIRMINGHAM Ala. Sep...),Health

BIRMINGHAM, Ala., Sept. 15 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S. Each partner will immediately begin meeting with key government officials in their respective territories to discuss peramivir's availability during this global health emergency.

BioCryst's new partners include:

• moksha8 Pharmaceuticals, Inc. for Brazil and Mexico
  

moksha8 Pharmaceuticals, Inc. has established broad commercial operations in Brazil and Mexico, the two key countries in Latin America that represent 75% of the $30 billion Latin America pharmaceutical market. The Company is currently selling over $200 million of products in the anti-infectives, central nervous system and inflammation indications under partnerships with Roche and Pfizer. Products in the Company's portfolio include key brands such as Rocephin, Bactrim, Lexotan and Rivotril.

• NT Pharma (Group) Co., Ltd. for China
  

NT Pharma was established in 1995 and has over 1,000 employees, corporate offices in Hong Kong and sales and marketing subsidiaries in Shanghai, Beijing, Guangzhou, Suzhou, Taizhou and Hainan for the distribution of pharmaceutical products including prescription medicine and vaccines. In 2009, the Group expects to achieve sales revenue of RMB 3 billion (U.S.$440 million), with a nationwide network that covers more than 100 cities, 1,500 hospital
'/>"/>